Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt No Debt
SYN's Cash to Debt is ranked higher than
89% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. SYN: No Debt )
SYN' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: No Debt

Interest Coverage No Debt
SYN's Interest Coverage is ranked higher than
68% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SYN: No Debt )
SYN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 33.78
M-Score: -7.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
ROE (%) -157.31
SYN's ROE (%) is ranked higher than
54% of the 877 Companies
in the Global Biotechnology industry.

( Industry Median: -28.59 vs. SYN: -157.31 )
SYN' s 10-Year ROE (%) Range
Min: -4484.82   Max: -48.04
Current: -157.31

-4484.82
-48.04
ROA (%) -146.24
SYN's ROA (%) is ranked higher than
50% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. SYN: -146.24 )
SYN' s 10-Year ROA (%) Range
Min: -1044.06   Max: -41.8
Current: -146.24

-1044.06
-41.8
ROC (Joel Greenblatt) (%) -1571.32
SYN's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. SYN: -1571.32 )
SYN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2835.38   Max: -112.64
Current: -1571.32

-2835.38
-112.64
Revenue Growth (%) -100.00
SYN's Revenue Growth (%) is ranked higher than
52% of the 646 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. SYN: -100.00 )
SYN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -100
Current: -100

EBITDA Growth (%) 108.00
SYN's EBITDA Growth (%) is ranked higher than
99% of the 621 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. SYN: 108.00 )
SYN' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 108
Current: 108

0
108
EPS Growth (%) 65.10
SYN's EPS Growth (%) is ranked higher than
98% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. SYN: 65.10 )
SYN' s 10-Year EPS Growth (%) Range
Min: 0   Max: 65.1
Current: 65.1

0
65.1
» SYN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

SYN Guru Trades in Q3 2013

Chuck Royce 428,669 sh (unchged)
» More
Q4 2013

SYN Guru Trades in Q4 2013

Chuck Royce 778,000 sh (+81.49%)
» More
Q1 2014

SYN Guru Trades in Q1 2014

Chuck Royce 276,000 sh (-64.52%)
» More
Q2 2014

SYN Guru Trades in Q2 2014

Chuck Royce 276,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with SYN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 12.40
SYN's P/B is ranked higher than
63% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. SYN: 12.40 )
SYN' s 10-Year P/B Range
Min: 2.78   Max: 18.11
Current: 12.4

2.78
18.11
EV-to-EBIT -5.78
SYN's EV-to-EBIT is ranked higher than
77% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SYN: -5.78 )
SYN' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -5.78

Current Ratio 7.49
SYN's Current Ratio is ranked higher than
86% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. SYN: 7.49 )
SYN' s 10-Year Current Ratio Range
Min: 0.03   Max: 58.44
Current: 7.49

0.03
58.44
Quick Ratio 7.49
SYN's Quick Ratio is ranked higher than
87% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. SYN: 7.49 )
SYN' s 10-Year Quick Ratio Range
Min: 0.03   Max: 58.44
Current: 7.49

0.03
58.44

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.70
SYN's Price/Net Cash is ranked higher than
82% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 80.40 vs. SYN: 15.70 )
SYN' s 10-Year Price/Net Cash Range
Min: 0.72   Max: 27.57
Current: 15.7

0.72
27.57
Price/Net Current Asset Value 15.70
SYN's Price/Net Current Asset Value is ranked higher than
80% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 41.80 vs. SYN: 15.70 )
SYN' s 10-Year Price/Net Current Asset Value Range
Min: 0.72   Max: 27.57
Current: 15.7

0.72
27.57
Price/Tangible Book 12.40
SYN's Price/Tangible Book is ranked higher than
69% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 8.73 vs. SYN: 12.40 )
SYN' s 10-Year Price/Tangible Book Range
Min: 0.56   Max: 25
Current: 12.4

0.56
25
Price/Median PS Value 1.10
SYN's Price/Median PS Value is ranked higher than
62% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. SYN: 1.10 )
SYN' s 10-Year Price/Median PS Value Range
Min: 0.49   Max: 0.81
Current: 1.1

0.49
0.81
Forward Rate of Return (Yacktman) -156.97
SYN's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -10.16 vs. SYN: -156.97 )
SYN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -156.97

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SFYB.Germany
Synthetic Biologics Inc. was incorporated in the State of Nevada. The company is a biotechnology company engaged in the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. It is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis, and has partnered the development of a treatment for fibromyalgia. It competes with Actelion Pharmaceuticals, Bayer Health Care, Biogen Idec, Eli Lilly & Co., Genzyme, GlaxoSmithKline Pharmaceuticals, Merck & Co., Pfizer, Novartis, Teva Pharmaceuticals and United Therapeutics.
» More Articles for SYN

Headlines

Articles On GuruFocus.com
Synodon Inc. – A Breakthrough Technology For Pipeline Safety Jan 28 2013 

More From Other Websites
Synthetic Biologics' SYN-005 Gets Orphan Drug Designation Sep 16 2014
Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome... Sep 16 2014
Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough... Sep 12 2014
Synthetic Biologics to Host Phase II Trimesta™ for Multiple Sclerosis Conference Call Sep 11 2014
Synthetic Biologics to Webcast September 16, 2014 Irritable Bowel Syndrome (IBS) Investor Day Sep 10 2014
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Sep 09 2014
Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough... Sep 08 2014
Synthetic Biologics Highlights New Data from C. difficile Program Presented at the 54th ICAAC Sep 07 2014
Synthetic Biologics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in... Sep 03 2014
Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly... Sep 02 2014
Synthetic Biologics (SYN) Looks Strong: Stock Gains 13.9% Sep 02 2014
Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API... Aug 28 2014
Synthetic Biologics Announces Presentation of Poster for SYN-004 C. difficile Program at IDWeek... Aug 26 2014
SYNTHETIC BIOLOGICS, INC. Financials Aug 22 2014
Synthetic Biologics (SYN) Jumps: Stock Adds 16% in Session Aug 21 2014
Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th... Aug 19 2014
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 14 2014
Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights Aug 14 2014
Synthetic Biologics to Host Irritable Bowel Syndrome (IBS) Investor Day Aug 13 2014
Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for... Aug 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK